Biohit Oyj has received the preliminary results on the clinical study, the purpose of which is to determine the capacity of the new BioAcetium product to eradicate Helicobacter pylori infection. Based on the results, Biohit Oyj has decided to conduct further examinations that will use longer treatment times. In further examinations BioAcetium will also be combined with an antibiotic that does not cause development of antibiotic-resistant strains of the bacteria.

The clinical study was conducted in cooperation with HUS Gastroenterology clinic (Hospital District of Helsinki and Uusimaa) and GastroLääkärit. The purpose of the study was to determine the new BioAcetium ability to treat Helicobacter pylori in individuals over 55 years of age who have not been diagnosed with a prior H. pylori infection.